Director Kurt Gustafson not seeking re-election at June 2022 annual meeting

Niagen Bioscience, Inc.

Gustafson notified ChromaDex on April 5, 2022 of decision.
He will remain on Board, Audit Committee, and Compensation Committee until June 2022 meeting.
Departure is not due to any disagreement with the Company on operations, policies, or practices.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Kurt Gustafson

Director

NAGE · Niagen Bioscience, Inc.

Filed: April 11, 2022, 7:59 PM ET

On April 5, 2022, Kurt Gustafson notified ChromaDex Corporation (the “Company”) of his intention not to stand for re-election as director of Board of Directors of the Company (the “Board”) and as a member of the Audit Committee and Compensation Committee of the Board.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Kurt Gustafson departed as Director at Niagen Bioscience, Inc..

Action: not stand for re-election
Role: Director

Exact text from the filing

On April 5, 2022, Kurt Gustafson notified ChromaDex Corporation (the “Company”) of his intention not to stand for re-election as director of Board of Directors of the Company (the “Board”) and as a member of the Audit Committee and Compensation Committee of the Board.

View on SEC.gov

Niagen Bioscience, Inc. filing history →

Source: SEC EDGAR

accession 0001628280-22-008931

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.